Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ATMPs

- PMLiVE

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

- PMLiVE

First Humira biosimilars reach EU market

World's biggest selling medicine to lose billions in sales

- PMLiVE

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

Trial could begin by year end

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

Spark sputters on haemophilia A gene therapy safety scare

Investors compare data unfavourably with BioMarin rival

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

- PMLiVE

Bluebird’s first gene therapy gets European fast track

For once, Europe set for approval and launch ahead of US

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

- PMLiVE

Christina Coughlin to leave Immunocore for Tmunity

UPenn pioneers building their own biotech company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links